Lonza Group (LONN) Stock Overview
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LONN Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 543.40 |
| 52 Week High | CHF 605.20 |
| 52 Week Low | CHF 454.60 |
| Beta | 0.89 |
| 1 Month Change | 12.86% |
| 3 Month Change | -2.83% |
| 1 Year Change | 0.78% |
| 3 Year Change | -5.36% |
| 5 Year Change | -2.58% |
| Change since IPO | 491.94% |
Recent News & Updates
Recent updates
Lonza Group's (VTX:LONN) Solid Earnings Are Supported By Other Strong Factors
Apr 09
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)?
Dec 22We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt
Dec 01Investors Interested In Lonza Group AG's (VTX:LONN) Earnings
Oct 24What Is Lonza Group AG's (VTX:LONN) Share Price Doing?
Sep 10Here's Why Lonza Group (VTX:LONN) Has A Meaningful Debt Burden
Aug 20Lonza Group AG (VTX:LONN) Not Flying Under The Radar
May 31Is It Too Late To Consider Buying Lonza Group AG (VTX:LONN)?
Apr 25
CDMO Focus And Vacaville Acquisition To Drive Operational Improvements By 2025
Focus on CDMO business and Vacaville acquisition to drive revenue growth and boost sales.Shareholder Returns
| LONN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 5.5% | 6.3% | 0.3% |
| 1Y | 0.8% | 2.4% | 13.5% |
Return vs Industry: LONN underperformed the Swiss Life Sciences industry which returned 2.4% over the past year.
Return vs Market: LONN underperformed the Swiss Market which returned 13.5% over the past year.
Price Volatility
| LONN volatility | |
|---|---|
| LONN Average Weekly Movement | 3.4% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.0% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: LONN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: LONN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 20,000 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms.
Lonza Group AG Fundamentals Summary
| LONN fundamental statistics | |
|---|---|
| Market cap | CHF 37.13b |
| Earnings (TTM) | CHF 909.00m |
| Revenue (TTM) | CHF 6.53b |
Is LONN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONN income statement (TTM) | |
|---|---|
| Revenue | CHF 6.53b |
| Cost of Revenue | CHF 4.18b |
| Gross Profit | CHF 2.35b |
| Other Expenses | CHF 1.44b |
| Earnings | CHF 909.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 22, 2026
| Earnings per share (EPS) | 13.01 |
| Gross Margin | 35.97% |
| Net Profit Margin | 13.92% |
| Debt/Equity Ratio | 54.3% |
How did LONN perform over the long term?
See historical performance and comparisonDividends
Does LONN pay a reliable dividends?
See LONN dividend history and benchmarks| Lonza Group dividend dates | |
|---|---|
| Ex Dividend Date | May 12 2026 |
| Dividend Pay Date | May 15 2026 |
| Days until Ex dividend | 24 days |
| Days until Dividend pay date | 27 days |
Does LONN pay a reliable dividends?
See LONN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/17 17:42 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lonza Group AG is covered by 47 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Xian Deng | Berenberg |